Anemia of inflammation: The hepcidin link

Current Opinion in Hematology

Volumn 12, Issue 2, 2005, Pages 107-111

  Roy, Cindy N ^a,b   Andrews, Nancy C ^a,b,c,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Anemia; Hemochromatosis; Hepcidin; Inflammation; Iron recycling

Indexed keywords

HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; PROTEIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ERYTHROCYTE; ERYTHROPOIESIS; HUMAN; INFLAMMATION; INTESTINE CELL; IRON ABSORPTION; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; LIVER CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; HOMEOSTASIS; HUMANS; INFLAMMATION; IRON;

EID: 14644436419     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200503000-00001     Document Type: Review

References (36)

1. Means RT Jr. The anaemia of infection. Baillieres Best Pract Res Clin Haematol 2000; 13:151-162.
2. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783-788.
3. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3;351-375.
4. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16:87-96.
5. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461-2463.
6. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271-1276. This article describes a real-time assessment of serum iron concentrations and HAMP excretion in human volunteers after infusion with IL-6 and after an oral iron dose. That HAMP excretion and serum iron are elevated immediately after an oral iron dose and then return to normal within days is consistent with the hypothesized mucosal block.
7. Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100:3776-3781.
8. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99:4596-4601.
9. Gehrke SG, Kulaksiz H, Herrmann T, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to serum transferrin saturation and non-transferrin-bound iron. Blood 2003; 102:371-376.
10. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276:7811-7819.
11. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037-1044.
12. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004; 124:123-124. This article describes reduced Hamp expression in thalassemic mice, despite hepatic iron loading. As for the hypotransferrinemic mice described in [7], this result indicates that Hamp is more responsive to the erythropoietic drive than hepatic iron stores.
13. Nicolas G, Viatte L, Bennoun M, et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29:327-335.
14. Finch C. Regulators of iron balance in humans. Blood 1994; 84:1697-1702.
15. Hahn PF, Bale WF, Ross JF, et al. Radioactive iron absorption by the gastro-intestinal tract: influence of anemia, anoxia, and antecedent feeding. J Exp Med 1943; 78:169-188.
16. Zhang AS, Xiong S, Tsukamoto H, et al. Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood 2004; 103:1509-1514. The localization of HFE has been disputed in the literature because of differences in antibody preparations. This important study used in situ hybridization to show HFE expression in hepatocytes.
17. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36:77-82. This article described the identification of HJV and showed a decrease in HAMP excretion in patients with mutations in HJV.
18. Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J Biol Chem 1999; 274:20826-20832.
19. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361:669-673.
20. Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet 2003; 34:102-107.
21. Nicolas G, Viatte L, Lou DQ, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003; 34:97-101.
22. Laftah AH, Ramesh B, Simpson RJ, et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103:3940-3944.
23. Roy CN, Custodio AO, De Graaf J, et al. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat Genet 2004; 36:481-485. This article demonstrates that Hfe-/- mice have an impaired ability for the development of hypoferremia in response to lipopolysaccharide, despite an intact type II acute-phase response. Insufficient Hamp induction in response to lipopolysaccharide in Hfe-/- mice may explain the diminished response.
24. Jacolot S, Le Gac G, Scotet V, et al. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103:2835-2840. This article describes more severe iron indices for patients with homozygous C282Y mutations and additional heterozygous mutations in HAMP.
25. Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97:2555-2560.
26. Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2-hemochromatosis. Blood 2004; Oct 14. [E-pub ahead of print.] This article describes decreased HAMP excretion in patients with mutations in TFR2.
27. Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2004; Sep 2. [E-pub ahead of print.] This article describes decreased Hamp expression in TfR2 mutant mice.
28. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33:21-22.
29. Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5′-UTR of the HAMP gene. Blood 2004; 104:2181-2183.
30. Delatycki M, Allen K, Gow P, et al. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clin Genet 2004; 65:378-383. This article describes a C78T mutation in HAMP, similar to the C70R mutation described in [28].
31. Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004; 13:1913-1918. This article describes more severe iron indices for patients with homozygous C282Y mutations and additional heterozygous mutations in HJV.
32. Krijt J, Vokurka M, Chang KT, et al. Expression of Rgmc, the murine ortholog of hemojuvelin gene, is modulated by development and inflammation, but not by iron status or erythropoietin. Blood 2004; Aug 16. [E-pub ahead of print.] This article investigates the regulation of Rgmc mRNA (the mouse HJV ortholog) in the liver and finds that Rgmc expression does not change at birth or in response to iron or erythropoietin. Rgmc expression is dramatically reduced in response to lipopolysaccharide, however.
33. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004. (in press) This article demonstrates in cultured cells a direct interaction between HAMP and Slc40A1/ferroportin that reduces cellular iron egress.
34. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108:619-623.
35. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32:131-138.
36. Rivera S, Liu L, Nemeth E, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2004; Oct 12. [E-pub ahead of print.] This article describes the use of tumor xenografts in NOD-SCID mice for chronic overexpression of Hamp. Anemia was observed for control tumors and for Hamp-producing tumors. Only Hamp-producing tumors decreased serum iron concentration and induced iron loading of hepatocytes.